The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Analysts have deemed LLY stock a “Strong Buy,” with an average target price of $984.29, indicating an upside potential of 12.1% from Friday’s closing price. Among the 24 analysts covering the stock, ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.